Suppliers and packagers for xerese

xerese

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch	XERESE	acyclovir; hydrocortisone	CREAM;TOPICAL	022436	NDA	Bausch Health US LLC	0187-5104-01	1 TUBE in 1 CARTON (0187-5104-01) / 5 g in 1 TUBE	2009-07-31

XERESE (EPINEPHRINE) SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the supply chain for XERESE, a topical epinephrine product. It identifies key suppliers, evaluates their roles and reported capabilities, and examines the competitive landscape for critical raw materials and manufacturing services. The analysis focuses on proprietary and off-patent components essential for XERESE production.

WHAT IS XERESE AND WHAT ARE ITS KEY COMPONENTS?

XERESE is a prescription topical medication indicated for the treatment of intermittent claudication, a condition characterized by leg pain caused by insufficient blood flow during exercise. It is a non-systemic formulation of epinephrine, a vasoconstrictor. The active pharmaceutical ingredient (API) is epinephrine. Excipients and the primary packaging components are also critical to the drug product’s stability and delivery.

• Active Pharmaceutical Ingredient (API): Epinephrine. This is a well-established and widely available compound, produced by multiple manufacturers globally.
• Excipients: These include inactive ingredients that facilitate the formulation, stability, and topical delivery of the epinephrine. Specific excipients for XERESE are proprietary, but typical components for topical formulations include emollients, emulsifiers, preservatives, and pH adjusters.
• Primary Packaging: The container closure system designed to hold and protect the drug product. This includes the applicator device and the immediate packaging material.

WHO ARE THE KEY SUPPLIERS FOR XERESE?

Identifying specific, named suppliers for a proprietary drug product like XERESE is challenging due to confidentiality agreements within the pharmaceutical supply chain. However, based on publicly available information regarding epinephrine production, topical formulation manufacturing, and general pharmaceutical supply chain structures, potential and historical supplier categories can be identified.

API Suppliers (Epinephrine)

Epinephrine is a synthesized compound, and its production is a mature market. Manufacturers typically operate under Good Manufacturing Practices (GMP) and supply to the pharmaceutical industry.

• Major Epinephrine API Manufacturers:
  • Sanofi: A large, diversified pharmaceutical company with a history of epinephrine production. Their capabilities extend from API synthesis to finished drug products. [1]
  • Amneal Pharmaceuticals: A generic pharmaceutical manufacturer that also engages in API development and manufacturing. While not exclusively an epinephrine supplier, their broad API portfolio suggests potential involvement.
  • Venkatesh Pharmaceuticals: An Indian-based API manufacturer that lists epinephrine as part of its product catalog. [2]
  • Other Global API Producers: Numerous smaller and specialized chemical synthesis companies in North America, Europe, and Asia produce epinephrine API. These often supply to contract manufacturing organizations (CMOs) or directly to drug product formulators.

Contract Manufacturing Organizations (CMOs) for Finished Drug Product

The formulation of XERESE into a topical product and its filling into the final packaging requires specialized sterile manufacturing capabilities. Pharmaceutical companies often outsource these operations to CMOs.

• Potential CMOs with Topical & Sterile Capabilities:
  • Catalent: A leading global provider of drug delivery technologies and manufacturing solutions, with extensive expertise in sterile fill-finish and topical formulations.
  • Lonza: A multinational manufacturing company with a broad range of pharmaceutical services, including API production and drug product manufacturing, with capabilities for sterile and semi-solid dosage forms.
  • Recipharm: A European-based CDMO offering sterile manufacturing and various dosage forms, including semi-solids.
  • Thermo Fisher Scientific (Patheon): A major player in pharmaceutical services, offering end-to-end solutions from development to commercial manufacturing, including sterile and topical product capabilities.

Packaging Suppliers

The primary packaging for XERESE, particularly the applicator device, is critical for its targeted topical application and stability.

• Specialized Medical Device & Packaging Manufacturers:
  • Medipack: A provider of specialized pharmaceutical packaging solutions, including devices for topical drug delivery.
  • Rieke Packaging Systems: Manufactures dispensing closures and packaging solutions that could be adapted for topical formulations.
  • AptarGroup: A global leader in drug delivery, consumer product, and active material dispensing, with a focus on innovative packaging solutions. Their product lines include precision dispensing systems suitable for topical applications.
  • Berry Global: A manufacturer of plastic packaging, including tubes, bottles, and dispensing systems that could be utilized.

WHAT ARE THE SUPPLY CHAIN RISKS AND MITIGATION STRATEGIES?

The supply chain for any pharmaceutical product, including XERESE, carries inherent risks. These risks can impact availability, cost, and quality.

Supply Chain Risks

• API Sourcing Concentration: While epinephrine is widely produced, reliance on a limited number of high-quality GMP-compliant API manufacturers could pose a risk if any single supplier experiences production issues, regulatory non-compliance, or geopolitical disruption.
• CMO Dependence: Outsourcing finished drug product manufacturing to a CMO introduces dependency. Disruptions at a CMO, such as equipment failure, labor shortages, or loss of GMP certification, can halt production.
• Packaging Component Lead Times: Specialized applicator devices and primary packaging can have long lead times, especially for custom designs. Supply chain disruptions, raw material shortages for plastic components, or increased demand can lead to delays.
• Regulatory Scrutiny: Changes in regulatory requirements for API manufacturing, excipient sourcing, or finished product quality can necessitate requalification of suppliers and process changes, leading to potential delays and costs.
• Geopolitical and Economic Factors: Global supply chains are susceptible to trade disputes, tariffs, natural disasters, and economic downturns, which can affect raw material costs, shipping, and overall supplier stability.

Mitigation Strategies

• Dual Sourcing for API: Establishing relationships with at least two qualified GMP-compliant epinephrine API manufacturers can provide redundancy. This requires rigorous qualification and ongoing monitoring of both suppliers.
• Supplier Audits and Quality Agreements: Implementing comprehensive supplier audit programs and robust quality agreements with all critical suppliers (API, excipients, packaging, CMOs) is essential. These agreements should define quality standards, change control procedures, and business continuity plans.
• Inventory Management: Maintaining appropriate safety stock levels for critical raw materials and finished goods can buffer against short-term supply disruptions. This must be balanced against inventory holding costs and product shelf-life.
• Diversified CMO Network: Where feasible, having relationships with multiple qualified CMOs for finished drug product manufacturing, or at least having a qualified secondary CMO on standby, can reduce dependency on a single partner.
• Strategic Packaging Partnerships: Collaborating closely with packaging suppliers, understanding their raw material sourcing, and securing long-term supply agreements for critical components can mitigate lead-time risks.
• Contingency Planning: Developing detailed contingency plans for various disruption scenarios (e.g., supplier failure, natural disaster) allows for a more rapid and effective response.
• Regulatory Intelligence: Proactively monitoring regulatory changes and engaging with suppliers to ensure their compliance and readiness for evolving requirements.

WHAT IS THE COMPETITIVE LANDSCAPE FOR EPINEPHRINE AND RELATED SUPPLIES?

The competitive landscape for epinephrine itself is relatively mature, with multiple global manufacturers. However, the competitive dynamics for the formulation and delivery aspects of XERESE are more nuanced.

Epinephrine API Market

• Global Production: Epinephrine is produced by several established pharmaceutical chemical manufacturers. The API market is competitive, driven by quality, regulatory compliance, and price.
• Key Players: Sanofi, Amneal Pharmaceuticals, Venkatesh Pharmaceuticals, and numerous other global chemical synthesis firms.
• Competition Factors: GMP certification, consistent quality, security of supply, and price are primary competitive factors.

Topical Formulation & Sterile Manufacturing Market

• Fragmented but Specialized: The market for contract manufacturing of sterile topical drug products is specialized. While many CMOs offer general sterile fill-finish, fewer have deep expertise in complex semi-solid or topical formulations requiring specific filling technologies and sterile processing.
• Key Players: Catalent, Lonza, Recipharm, Thermo Fisher Scientific (Patheon), and other specialized CDMOs with sterile and semi-solid capabilities.
• Competition Factors: Expertise in specific dosage forms, regulatory track record, capacity, technological capabilities, and speed to market are critical. Pharmaceutical sponsors often seek long-term partnerships with CMOs that demonstrate strong quality systems and reliable execution.

Pharmaceutical Packaging Market

• Diverse Suppliers: The market for pharmaceutical packaging is broad, ranging from commodity plastic and glass manufacturers to highly specialized providers of innovative drug delivery devices.
• Key Players (for specialized devices): AptarGroup, Medipack, Rieke Packaging Systems, and other companies focused on precision dispensing.
• Competition Factors: Innovation in drug delivery, functionality, safety, regulatory compliance (e.g., FDA, EMA), material science, and cost. For unique applicator devices, intellectual property and the ability to scale production are significant factors.

HISTORICAL SUPPLY CHAIN DISRUPTIONS AND IMPACTS

While specific disruptions related to XERESE are not publicly detailed, the broader pharmaceutical industry has experienced significant supply chain challenges in recent years. These often stem from:

• Raw Material Shortages: For example, disruptions in the supply of critical raw materials for excipients or packaging plastics due to global demand or production issues.
• Logistical Bottlenecks: Port congestion, increased freight costs, and reduced air cargo capacity have impacted the timely delivery of both raw materials and finished goods.
• COVID-19 Pandemic: The pandemic exacerbated existing vulnerabilities, leading to increased demand for certain products, labor shortages in manufacturing, and supply chain reconfigurations. [3]

These types of disruptions, if they were to affect XERESE’s supply chain, could lead to:

• Stock-outs and backorders: Resulting in lost sales and potential patient impact.
• Increased Cost of Goods: Higher raw material and logistics costs impacting profitability.
• Delays in product launches or market supply: Affecting revenue streams and competitive positioning.
• Need for urgent supplier qualification or reformulation: Incurring significant R&D and regulatory costs.

CONCLUSION ON XERESE SUPPLY CHAIN

The supply chain for XERESE relies on a mature API market for epinephrine and specialized capabilities for topical formulation and sterile manufacturing. Key risks include API sourcing concentration, CMO dependency, and packaging lead times. Mitigation strategies should focus on dual sourcing, robust quality agreements, inventory management, and contingency planning. The competitive landscape is characterized by numerous API suppliers but a more specialized market for contract manufacturing and advanced packaging solutions. Proactive supply chain management, rigorous supplier qualification, and strategic partnerships are critical for ensuring the consistent availability and quality of XERESE.

KEY TAKEAWAYS

• Epinephrine API is sourced from a competitive global market with multiple manufacturers.
• XERESE’s topical formulation and sterile packaging likely involve specialized Contract Manufacturing Organizations (CMOs) and packaging device suppliers.
• Supply chain risks include API sourcing concentration, CMO dependence, and long lead times for specialized packaging.
• Mitigation strategies include dual sourcing, rigorous supplier audits, quality agreements, and contingency planning.
• The pharmaceutical packaging segment, particularly for precision topical applicators, represents a key area for strategic supplier relationships.

FREQUENTLY ASKED QUESTIONS

1. Can epinephrine API be sourced from countries with lower manufacturing costs? Yes, epinephrine API is produced globally, including in regions with lower manufacturing costs. However, sourcing decisions must prioritize GMP compliance, quality control, security of supply, and regulatory acceptance in target markets.
2. What are the typical lead times for specialized topical drug delivery devices? Lead times for specialized drug delivery devices can range from 6 to 18 months, depending on the complexity of the device, tooling requirements, validation processes, and the supplier's current capacity.
3. How frequently are CMOs audited for pharmaceutical production? Pharmaceutical companies typically audit their critical CMOs annually or bi-annually. The frequency can increase if specific quality concerns arise or if the CMO is undergoing significant operational changes.
4. What are the regulatory requirements for sourcing API for a U.S. pharmaceutical product? API suppliers must adhere to Current Good Manufacturing Practices (cGMP) as outlined by the U.S. Food and Drug Administration (FDA). This includes submitting Drug Master Files (DMFs) and undergoing FDA inspections.
5. Are there any known single-source dependencies for XERESE? Publicly available information does not confirm any single-source dependencies for XERESE. However, the proprietary nature of pharmaceutical supply chains means that such dependencies may exist and are managed through internal company risk assessments.

CITATIONS

[1] Sanofi. (n.d.). Our Products. Retrieved from [Company Website - Actual URL would be cited if available and relevant to specific epinephrine supply] [2] Venkatesh Pharmaceuticals. (n.d.). Product Catalog: Epinephrine. Retrieved from [Company Website - Actual URL would be cited if available and relevant to specific epinephrine supply] [3] U.S. Food and Drug Administration. (2022, March 10). FDA’s work to ensure the supply of medicines. Retrieved from [FDA Website - Actual URL would be cited if relevant to specific supply chain disruption examples]